Prelude announces multiple clinical, preclinical presentations at AACR-NCI-EORTC

Prelude Therapeutics announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 – 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude’s CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for our SMARCA2 degrader compound, PRT3789. “This additional data from our solid tumor trial investigating our potent and selective CDK9 inhibitor, PRT2527, continues to support a best-in-class safety and target engagement profile for the molecule. A second Phase 1 clinical trial in patients with hematological cancers is also underway, with initial data expected in 1H 2024,” stated Jane Huang, President and Chief Medical Officer, Prelude Therapeutics.